Roche’s Genentech is out with a new threat to Shire’s hemophilia franchise—but the Dublin drugmaker’s CEO isn’t too concerned.
Created by Janssen along with the American Cancer Society, Cancer Support Community and CancerCare, the website was years in the making.
Three major regulatory bodies – FDA, EMA and Health Canada – changed their guidelines to drug naming. How could these changes impact drug launch timelines?
GlaxoSmithKline may have some new Nucala competition in severe asthma, but it also has a new market all to itself.
Pharma TV ad spending has already officially topped last year with a total of $3.2 billion through the end of November, according to iSpot.tv data.
AbbVie and Roche are working to widen Venclexta’s patient population in previously treated chronic lymphocytic leukemia, and new data should help.
J&J has succeeded in moving Darzalex earlier into multiple myeloma therapy, and it now has data that could help it win a first-line nod.
With full data out from a trial of Seattle Genetics’ Adcetris classical Hodgkin lymphoma, at least one analyst is iffy about the drug’s prospects.
With Tecentriq and Avastin's trial win over Sutent in first-line kidney cancer, Roche scored new points in its quest to advance the combo.
J&J and AbbVie racked up new long-term Imbruvica data that will come in handy as they try to ward off a new AstraZeneca competitor.
After a near-fatal heart attack, Biggest Loser's Bob Harper has teamed with Brilinta-maker AstraZeneca to reach other survivors.